相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Quercetin exerts anti-melanoma activities and inhibits STAT3 signaling
Hui-Hui Cao et al.
BIOCHEMICAL PHARMACOLOGY (2014)
The flavonoid quercetin in disease prevention and therapy: Facts and fancies
Maria Russo et al.
BIOCHEMICAL PHARMACOLOGY (2012)
Quercetin abrogates IL-6/STAT3 signaling and inhibits glioblastoma cell line growth and migration
Jonathan Michaud-Levesque et al.
EXPERIMENTAL CELL RESEARCH (2012)
Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells
Guillaume Jacquemin et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models
Robert Kleemann et al.
ATHEROSCLEROSIS (2011)
STAT3 Inhibition Is a Therapeutic Strategy for ABC-like Diffuse Large B-Cell Lymphoma
Anna Scuto et al.
CANCER RESEARCH (2011)
Quercetin and Cancer Chemoprevention
Lara Gibellini et al.
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE (2011)
Blockade of Oxidized LDL-Triggered Endothelial Apoptosis by Quercetin and Rutin through Differential Signaling Pathways Involving JAK2
Jung-Suk Choi et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2009)
STATs in cancer inflammation and immunity: a leading role for STAT3
Hua Yu et al.
NATURE REVIEWS CANCER (2009)
Drug therapy: Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma
Bruce D. Cheson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas
B. Belinda Ding et al.
BLOOD (2008)
A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcino genic properties
M. Harwood et al.
FOOD AND CHEMICAL TOXICOLOGY (2007)
Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis
E. Suzuki et al.
ONCOGENE (2007)
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2006)
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
W Hiddemann et al.
BLOOD (2005)
Rituximab inhibits p38 MAPK activity in 2F7 BNHL and decreases IL-10 transcription: Pivotal role of p38 MAPK in drug resistance
MI Vega et al.
ONCOGENE (2004)
The stats of cancer - New molecular targets come of age
H Yu et al.
NATURE REVIEWS CANCER (2004)
Quercetin, a flavonoid phytoestrogen, ameliorates experimental allergic encephalomyelitis by blocking IL-12 signaling through JAK-STAT pathway in T lymphocyte
G Muthian et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2004)
Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma
Y Aoki et al.
BLOOD (2003)
Roles of activated Src and Stat3 signaling in melanoma tumor cell growth
G Niu et al.
ONCOGENE (2002)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
分享论文
